Mdxhealth Earnings Call Highlights Fast Growth, Rising Costs

Mdxhealth S.A. ((MDXH)) has held its Q4 earnings call. Read on for the main highlights of the call.

Mdxhealth’s latest earnings call struck a tone of robust growth tempered by near-term financial strain. Management highlighted surging test volumes and progress integrating the ExoDx acquisition, while acknowledging rising operating losses, integration costs, and a small revenue adjustment, yet reiterated confidence in reaching meaningful profitability by 2026.

Explosive Unit Growth Led by Liquid Tests

Q4 total billable volume reached about 38,000 tests, up 62% year over year. Liquid-based assays were the standout, with volumes jumping 128%, reflecting strong ExoDx adoption and successful conversion of legacy SelectMDx customers.

Solid Quarterly Revenue and Margin Expansion

Fourth-quarter revenue climbed 19% from $24.7 million to $29.5 million. Gross profit rose 20% to $18.7 million, nudging gross margin up to 63.2% from 62.7%, underscoring the economic strength of the testing portfolio despite mix shifts.

Full-Year Revenue and Minor Pre-Release Revision

For the full year, Mdxhealth reported revenue of $107.9 million, about $1 million below its preliminary estimate. Management tied the revision to rationalizing closing processes after the ExoDx deal and stressed that this accounting cleanup does not alter its 2026 outlook.

ExoDx Integration and New Cross-Selling Potential

The company began integrating ExoDx in Q4 and transitioned all SelectMDx users to ExoDx during the period. This consolidation is already driving operating efficiencies and sets the stage for cross-selling across a broader prostate cancer testing menu.

Operational Gains and Clinical Programs Advance

Operationally, Mdxhealth now offers what it calls best-in-class tissue turnaround times of five days or less. On the clinical front, completion of the GPS PROMPT study and launch of GPS PROTECT, along with strong enrollment in the UK PROTECT trial, could help elevate GPS positioning in key clinical guidelines.

Earnout Amendment Boosts Capital Flexibility

An amended earnout agreement with Exact Sciences reduces the upcoming payment by nearly $20 million and pushes remaining obligations back by a year. This move eases near-term cash pressure and offers more breathing room to fund integration and growth initiatives.

Operating and Net Losses Deepen

Despite growth, profitability moved the wrong way, with Q4 operating loss rising 14% to $5.3 million. Net loss widened 31% to $8.9 million, driven largely by acquisition-related costs and a $3.1 million increase in net financial expenses, only partly offset by a tax gain.

Adjusted EBITDA More Negative on Higher Costs

Adjusted EBITDA for the quarter was a negative $2.1 million versus negative $1.4 million a year earlier. Management linked the deterioration to integration-related spending and higher ongoing operating costs as the combined business ramps.

Integration Drives OpEx and Near-Term Volatility

Increased headcount and other expenses tied to ExoDx are weighing on operating loss and adjusted EBITDA. Executives cautioned that some integration “chop” is likely through Q1 as systems and teams are fully aligned, before efficiencies start to show through.

Tissue Volume Softness and ASP Mix Pressure

Tissue-based test volumes slipped 5% year over year, even as liquids surged. Average selling prices for tissue dipped by about $100 quarter over quarter, reflecting a shift toward lower-priced ConfirmMDx relative to the higher-reimbursed GPS assay and adding some ASP volatility.

Revenue Recognition Complexity Post-Acquisition

The $1 million downward adjustment to pre-released 2025 revenue highlights challenges blending reporting systems after the ExoDx acquisition. Management framed this as a one-time issue tied to standardizing closing processes rather than a signal of underlying demand weakness.

Lean Cash Position Underlines Execution Risk

Mdxhealth ended the year with $29 million in cash and cash equivalents, a modest cushion given continued losses and integration spending. The company argued that the earnout amendment improves flexibility, but investors will watch cash burn and funding options closely.

2026 Guidance Targets High Growth and Margin Turnaround

Looking ahead, management reiterated 2026 revenue guidance of $137–$140 million, implying about 28% growth driven mainly by volume rather than pricing. ExoDx is expected to contribute more than $20 million in 2026, with the company aiming to exit that year at roughly a 10% adjusted EBITDA margin once sales integration and cross-training are completed.

Mdxhealth’s call presented a classic growth story: rapid volume expansion, product integration, and improving operational metrics set against heavier losses and a tight cash balance. If management can execute on integration, deliver its 2026 growth and margin goals, and manage capital prudently, the current profitability pressure may prove a temporary detour on a path to stronger operating leverage.